Bezuclastinib + Sunitinib
Bezuclastinib 600 mg + sunitinib 37.5 mg
600 mg + 37.5 mg · ITT
GIST after imatinib (n = 204)
Comparator: sunitinib 37.5 mg
objective response rate (BICR): 46%, data cutoff 09.30.2025
Peak · NCT05208047
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
GIST pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
18 arms have a reported figure in this set.
Bezuclastinib 600 mg + sunitinib 37.5 mg
600 mg + 37.5 mg · ITT
GIST after imatinib (n = 204)
Comparator: sunitinib 37.5 mg
objective response rate (BICR): 46%, data cutoff 09.30.2025
Peak · NCT05208047
Sunitinib 37.5 mg continuous
37.5 mg · ITT
GIST after imatinib (n = 209)
objective response rate (BICR): 26%, data cutoff 09.30.2025
Peak · NCT05208047
Imatinib 400 mg daily
400 mg · ITT
unresectable or metastatic KIT (CD117) positive GIST
best overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)
Imatinib 400 mg
400 mg · ITT
KIT (CD117) positive unresectable or metastatic GIST
Comparator: imatinib 600 mg
objective response rate (SWOG): 68.5%, up to 36 months
Imatinib 600 mg
600 mg · ITT
KIT (CD117) positive unresectable or metastatic GIST
Comparator: imatinib 400 mg
objective response rate (SWOG): 67.6%, up to 36 months
Avapritinib 300 or 400 mg, PDGFRA exon 18
300 or 400 mg · Single arm
unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43)
overall response rate (independent review): 84%, median follow up 10.6 months
NAVIGATOR · NCT02508532
Avapritinib, PDGFRA D842V subgroup
300 or 400 mg · Single arm
PDGFRA D842V (n = 38)
overall response rate (independent review): 89%, median follow up 10.6 months
NAVIGATOR · NCT02508532
Avapritinib 300 mg
300 mg · ITT
3L or later GIST (n = 240)
Comparator: regorafenib 160 mg
objective response rate: 17.1%, primary analysis
VOYAGER · NCT03465722
Regorafenib 160 mg
160 mg · ITT
3L or later GIST (n = 236)
objective response rate: 7.2%, primary analysis
VOYAGER · NCT03465722
Olverembatinib 30 to 50 mg every other day
30 to 50 mg · Single arm
SDH-deficient GIST (n = 26)
partial response as best response: 23.1%, cutoff 11.13.2025
HQP1351SJ0003 · NCT03594422
Velzatinib 300 mg tablet (or 400 mg capsule), 2L
300 mg · Single arm
2L advanced GIST (n = 46)
objective response rate: 35%, cutoff 12.15.2025
StrateGIST 1 · NCT05489237
Velzatinib, 1L
300 mg · Single arm
1L advanced GIST (n = 18)
unconfirmed objective response rate: 61%, median follow up 6.4 months
StrateGIST 1 · NCT05489237
NB003, 2L to 4L or later
not stated in source · Single arm
GIST 2L to 4L or later (n = 158)
objective response rate: 28.5%, data as of March 2025
NB003 Phase 1 · NCT04936178
NB003, 3L subgroup
not stated in source · Single arm
GIST 3L (n not stated in source)
objective response rate: 46.7%, data as of March 2025
NB003 Phase 1 · NCT04936178
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib, sunitinib and regorafenib
Comparator: placebo
objective response rate (BICR): 9%, primary analysis
INVICTUS · NCT03353753
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib (ITT n = 226)
Comparator: sunitinib 50 mg 4/2
objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03
INTRIGUE · NCT03673501
Sunitinib 50 mg 4/2
50 mg · ITT
GIST after imatinib (ITT n = 227)
objective response rate, KIT exon 11 ITT: 14.6%, primary analysis
INTRIGUE · NCT03673501
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.